Breast Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_5_3369 - Prospective Study of 3-Fraction Intra-Cavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Prospective Study of 3-Fraction Intra-Cavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen
K. R. Jethwa1, K. Gonuguntla1, S. M. Wick1, L. A. Vallow2, C. L. Deufel1, T. J. Whitaker1, K. M. Furutani1, K. J. Ruddy3, T. J. Hieken4, K. S. Corbin1, S. S. Park1, and R. W. Mutter1; 1Department of Radiation Oncology, Mayo Clinic, Rochester, MN, 2Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, 3Division of Medical Oncology, Mayo Clinic, Rochester, MN, 4Department of Surgery, Mayo Clinic, Rochester, MN

Purpose/Objective(s): The optimal dose and fractionation for accelerated partial breast irradiation (APBI) is not known. We evaluated 3-fraction brachytherapy APBI in the context of a prospective clinical trial. Our purpose is to report early adverse effects and patient-reported outcomes (PROs) of this novel regimen.

Materials/Methods: Eligible women were ≥ 50 years of age with ≤2 cm estrogen receptor positive, sentinel lymph node (SLN) negative invasive or in-situ breast cancer treated with breast conserving surgery. After frozen section pathology assessment of negative surgical margins and SLN(s), a multi-channel intra-cavitary brachytherapy catheter was placed intraoperatively. APBI was initiated on the second weekday after surgery after permanent section pathology confirmation. The prescription was 21 Gy in 3, once daily, fractions targeting the lumpectomy cavity with a 1 cm expansion. Common toxicity criteria for adverse effects (CTCAE v 4.0), 10-point linear analog scales, PROs version of the CTCAE (PRO-CTCAE), and Harvard Breast Cosmesis Scale (HBCS) were utilized for provider and patient-reported assessments.

Results: 73 women, median age 66 years, were treated for invasive breast cancer (79%) or ductal carcinoma in situ (21%) between 2015 and 2017. Tumor grade was 1-2 in 88%. The median time to completion of all locoregional therapy (surgery and radiotherapy) was 6 days. After 14 months median follow-up, two patients (3%) had developed breast infections that resolved with oral antibiotics. There was no other treatment-associated adverse effects ≥ grade 2. The grade 1 seroma rate at 3 months was 20% (11/56 evaluable patients) which dropped to 8% (4/49) at 12 months; none required intervention. PROs are summarized in table 1. At 12 months, 91% reported overall QoL between 8 and 10 and patient-reported cosmesis was good or excellent in 95%. All patients were alive without relapse at the last follow-up.

Conclusion: 3-fraction, once daily, breast brachytherapy was associated with favorable early physician and PROs. These early results compare favorably with other reports including the more universally employed twice daily (3.4 Gy x 10) fractionation being studied in NSABP B-39. A randomized trial comparing these two approaches is warranted.
Table 1: Patient-Reported Outcomes associated with 3-fraction brachytherapy APBI
PROs LASA 10 Baseline (n=56) Post-RT (n=51) 3 month (n=44) 6 month (n=46) 12 month (n=35)
Quality of Lifeα 8-10 95% 96% 89% 96% 91%
4-7 4% 2% 7% 2% 9%
1-3 1% 2% 4% 2% 0%
Breast Cosmesis Excellent 55% 41% 50% 65% 69%
Good 45% 49% 39% 26% 26%
Fair 0% 10% 9% 9% 6%
Poor 0% 0% 2% 0% 0%
Painβ 0-3 61% 69% 86% 91% 86%
4-6 32% 22% 7% 4% 9%
7-10 7% 10% 7% 4% 6%
Fatigueβ 0-3 61% 55% 75% 63% 71%
4-6 25% 37% 16% 24% 12%
7-10 14% 8% 9% 13% 17%
Skin Burns None 100% 90% 88% 96% 100%
Mild 0% 8% 12% 2% 0%
Moderate 0% 0% 0% 0% 0%
Severe 0% 0% 0% 0% 0%
Very Severe 0% 2% 0% 2% 0%
LASAα: Reported on a scale of 1-10 (1 indicating “worst” and 10 indicating “best”) LASAβ: Reported on a scale of 1-10 (1 indicating “none” and 10 indicating “as bad as it can be”)

Author Disclosure: K.R. Jethwa: None. K. Gonuguntla: None. S.M. Wick: None. K.J. Ruddy: None. R.W. Mutter: Research Grant; ASTRO.

Send Email for Krishan Jethwa


Assets

TU_5_3369 - Prospective Study of 3-Fraction Intra-Cavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Prospective Study of 3-Fraction Intra-Cavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen